| 1.38 -0.49 (-26.2%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.55 | 1-year : | 3.49 |
| Resists | First : | 2.18 | Second : | 2.99 |
| Pivot price | 1.15  |
|||
| Supports | First : | 0.89 | Second : | 0.74 |
| MAs | MA(5) : | 1.3 |
MA(20) : | 1.12 |
| MA(100) : | 1.66 |
MA(250) : | 2.75 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 35.7 |
D(3) : | 45.6 |
| RSI | RSI(14): 55.1 |
|||
| 52-week | High : | 5.94 | Low : | 0.89 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ POAI ] has closed below upper band by 23.7%. Bollinger Bands are 14.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.55 - 1.56 | 1.56 - 1.56 |
| Low: | 1.19 - 1.2 | 1.2 - 1.21 |
| Close: | 1.37 - 1.38 | 1.38 - 1.39 |
Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient's body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.
Fri, 26 Jul 2024
Predictive Oncology Announces Exercise of Warrants for $1.26 Million Gross Proceeds - EIN News
Fri, 26 Jul 2024
Predictive Oncology Announces Exercise of Warrants for $1.26 Million Gross Proceeds - StockTitan
Thu, 25 Jul 2024
Why Is Predictive Oncology (POAI) Stock Up 70% Today? - InvestorPlace
Thu, 25 Jul 2024
Why Predicitive Oncology Stock Is Soaring - Benzinga
Thu, 25 Jul 2024
Predictive Oncology Enters Biomarker Discovery Market After Successful Retrospective Ovarian Cancer Study Yields Compelling Results - StockTitan
Wed, 29 May 2024
3 Penny Stocks to Watch Now - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 0 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 3.84e+006 (%) |
| Held by Institutions | 3.5 (%) |
| Shares Short | 266 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.403e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 9.6 % |
| Return on Equity (ttm) | -51.5 % |
| Qtrly Rev. Growth | 1.96e+006 % |
| Gross Profit (p.s.) | 64.56 |
| Sales Per Share | -112.73 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -3.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 1.6 |
| Dividend | 0 |
| Forward Dividend | 52000 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|